Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
- PMID: 36759050
- PMCID: PMC9903148
- DOI: 10.1016/j.eimce.2022.04.014
Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
Comment on
-
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. N Engl J Med. 2022. PMID: 35172054 Free PMC article. Clinical Trial.
References
-
- Reina J., Iglesias C. Nirmatrelvir más ritonavir (Paxlovid) una potente combinación inhibidora de la proteasa 3CLpro del SARS-CoV-2. Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combinationRev Esp Quimioter. 2022 doi: 10.37201/req/002.2022. reina21feb2022. Spanish. Epub ahead of print. PMID: 35183067. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
